BML Capital Management, LLC
ZIONSVILLE, IN · Quarter end: Sep 30, 2026 · Filed with SEC: Nov 6, 2026 · Open the SEC source ↗
Portfolio Return (1Y)——
Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.$186.4M2026 Q3+ $1.2M options (notional, not included)
Positions20
Top-10 ConcentrationPercent of the portfolio in the 10 largest holdings. High means the fund is concentrated in few stocks.89.0%
What Changed This Quarter?
Top Holdings
ACRS
Aclaris Therapeutics
30.7%
AVIR
Atea Pharmaceuticals
18.8%
ENGN
enGene Therapeutics
7.1%
PMVP
PMV Pharmaceuticals
6.5%
KHC
Kraft Heinz
5.8%
TLYS
Tilly'S
5.3%
KMX
Carmax
5.1%
OM
Outset Medical
4.0%
New / Increased
3 new · 4 increased
SEERNEW
Seer
2.6%
LENZNEW
Lenz Therapeutics
0.6%
KPTINEW
Karyopharm Therapeutics
0.0%
CNTB
Connect Biopharma
2.3%
+574.1%
PMVP
PMV Pharmaceuticals
6.5%
+37.5%
KHC
Kraft Heinz
5.8%
+2.2%
Oramed Pharma…
Oramed Pharmaceuticals
2.2%
+2.1%
Reduced / Exited
4 reduced · 1 sold out
ACRS
Aclaris Therapeutics
30.7%
-8.5%
TSLAPUT
Tesla
0.4%
-60.0%
AVIR
Atea Pharmaceuticals
18.8%
-2.9%
JANX
Janux Therapeutics
1.4%
-2.5%
CORZPUTEXIT
Core Scientific
0.2%
Read the 2026-Q2 quarterly report · 13F Filing Calendar
13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.